EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
ジャーナル・号・ページ	Structure, Vol. 23, Page 407-417, Year 2015
掲載日	2014年7月14日 (構造データの登録日)
著者	Huber, E.M. / Heinemeyer, W. / Groll, M.
リンク	Structure / PubMed:25599643
手法	X線回折
解像度	2.3 - 3.1 Å
構造データ	PDB-4qux: yCP beta5-A49T-mutant 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4quy: yCP beta5-A49S-mutant 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qv0: yCP beta5-A49T-A50V-double mutant 手法: X-RAY DIFFRACTION / 解像度: 3.1 Å PDB-4qv1: yCP beta5-M45A mutant 手法: X-RAY DIFFRACTION / 解像度: 2.5 Å PDB-4qv3: yCP beta5-M45V mutant 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qv4: yCP beta5-M45T mutant 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-4qv5: yCP beta5-M45I mutant 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-4qv6: yCP beta5-A49V mutant 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qv7: yCP beta5-A50V mutant 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qv8: yCP beta5-C52F mutant 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qv9: yCP beta5-C63F mutant 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qvl: yCP in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qvm: yCP beta5-M45A mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qvn: yCP beta5-M45V mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qvp: yCP beta5-M45T mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.3 Å PDB-4qvq: yCP beta5-M45I mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qvv: yCP beta5-A49V mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qvw: yCP beta5-A49S-mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qvy: yCP beta5-A49T-mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.51 Å PDB-4qw0: yCP beta5-A49T-A50V-double mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qw1: yCP beta5-A50V mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qw3: yCP beta5-C63F mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qw4: yCP in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qw5: yCP beta5-M45A mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qw6: yCP beta5-M45V mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qw7: yCP beta5-M45T mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-4qwf: yCP beta5-M45I mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qwg: yCP beta5-A49V mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qwi: yCP beta5-A49S-mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qwj: yCP beta5-A49T-mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qwk: yCP beta5-A49T-A50V-double mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qwl: yCP beta5-A50V mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qwr: yCP beta5-C52F mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qws: yCP beta5-C63F mutant in complex with carfilzomib 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qwu: yCP beta5-C52F mutant in complex with bortezomib 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qwx: yCP in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qxj: yCP beta5-M45A mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qz0: yCP beta5-M45V mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qz1: yCP beta5-M45T mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qz2: yCP beta5-M45I mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-4qz3: yCP beta5-A49V mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qz4: yCP beta5-A49S mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qz5: yCP beta5-A49T-mutant in complex with ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qz6: yCP beta5-A49T-A50V double mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4qz7: yCP beta5-A50V mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-4qzw: yCP beta5-C52F mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 3.0 Å PDB-4qzx: yCP beta5-C63F mutant in complex with the epoxyketone inhibitor ONX 0914 手法: X-RAY DIFFRACTION / 解像度: 2.6 Å PDB-4qzz: yCP in complex with Omuralide 手法: X-RAY DIFFRACTION / 解像度: 2.9 Å PDB-4r00: yCP beta5-C52F mutant in complex with Omuralide 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å
化合物	ChemComp-MG: Unknown entry / マグネシウムジカチオン ChemComp-HOH: WATER / 水 ChemComp-CL: Unknown entry / クロリド / 塩化物 ChemComp-BO2: N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE / ボルテゾミブ / 薬剤, 抗がん剤YM / ボルテゾミブ ChemComp-3BV: N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide / 薬剤, 抗がん剤, 阻害剤YM / カルフィルゾミブ ChemComp-MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID / 2-モルホリノエタンスルホン酸 / pH緩衝剤YM / MES (緩衝剤) ChemComp-04C: 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol ChemComp-NA: Unknown entry / ナトリウムカチオン ChemComp-SLA*: Omuralide, open form
由来	saccharomyces cerevisiae (パン酵母)
キーワード	HYDROLASE (加水分解酵素) / Cancer (悪性腫瘍) / Proteasome (プロテアソーム) / Bortezomib (ボルテゾミブ) / Drug Resistance (薬剤耐性) / Binding Analysis / HYDROLASE/HYDROLASE INHIBITOR / HYDROLASE-HYDROLASE INHIBITOR complex